{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:52:18Z","timestamp":1784195538878,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.bone.2016.04.026","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T19:21:47Z","timestamp":1462476107000},"page":"73-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Letter to the editor in response to the commentary, \"Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics"],"prefix":"10.1016","volume":"89","author":[{"given":"Benjamin Z.","family":"Leder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri-Anne","family":"Burnett-Bowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Bouxsein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Neer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.04.026_bb0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bone.2016.02.009","article-title":"Commentary: concurrent administration of PTH and antiresorptives: additive effects or DXA cosmetics","volume":"86","author":"Eriksen","year":"2016","journal-title":"Bone"},{"issue":"15","key":"10.1016\/j.bone.2016.04.026_bb0010","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2016.04.026_bb0015","first-page":"jc20161160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2016.04.026_bb0020","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): A randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9886","key":"10.1016\/j.bone.2016.04.026_bb0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.04.026_bb0030","first-page":"jc20153698","article-title":"Effect of teriparatide on bone formation in the human femoral neck","author":"Cosman","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"41","key":"10.1016\/j.bone.2016.04.026_bb0035","doi-asserted-by":"crossref","first-page":"29809","DOI":"10.1074\/jbc.M113.485938","article-title":"Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes","volume":"288","author":"Rhee","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.bone.2016.04.026_bb0040","doi-asserted-by":"crossref","first-page":"28164","DOI":"10.1074\/jbc.M110.101964","article-title":"Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL","volume":"285","author":"Pierroz","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.04.026_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2822","article-title":"Effects of daily or cyclic teriparatide on bone formation in the iliac crest in women on no prior therapy and in women on alendronate","author":"Dempster","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"9999","key":"10.1016\/j.bone.2016.04.026_bb0050","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.04.026_bb0055","series-title":"Effects of Abaloparatide on Vertebral and Non-vertebral Fracture Incidence in Postmenopausal Women with Osteoporosis \u2014 Results of the Phase 3 Active Trial Endocrine Society's 97th Annual Meeting","author":"Miller","year":"2015"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T07:58:31Z","timestamp":1536739111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216301132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":11,"alternative-id":["S8756328216301132"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.04.026","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor in response to the commentary, \"Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}